WallStSmart

Eton Pharmaceuticals Inc (ETON)vsMerck & Company Inc (MRK)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Merck & Company Inc generates 81215% more annual revenue ($65.01B vs $79.95M). MRK leads profitability with a 28.1% profit margin vs -5.8%. MRK earns a higher WallStSmart Score of 59/100 (C).

ETON

Hold

35

out of 100

Grade: F

Growth: 7.3Profit: 4.5Value: 5.0Quality: 5.0

MRK

Buy

59

out of 100

Grade: C

Growth: 4.0Profit: 9.5Value: 4.7Quality: 4.8
Piotroski: 3/9
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for ETON.

MRKOvervalued (-13.2%)

Margin of Safety

-13.2%

Fair Value

$96.48

Current Price

$109.18

$12.70 premium

UndervaluedFair: $96.48Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ETON2 strengths · Avg: 9.0/10
Revenue GrowthGrowth
82.7%10/10

Revenue surging 82.7% year-over-year

Operating MarginProfitability
21.0%8/10

Strong operational efficiency at 21.0%

MRK6 strengths · Avg: 9.2/10
Market CapQuality
$274.03B10/10

Mega-cap, among the largest globally

Return on EquityProfitability
36.9%10/10

Every $100 of equity generates 37 in profit

Operating MarginProfitability
32.8%10/10

Strong operational efficiency at 32.8%

Profit MarginProfitability
28.1%9/10

Keeps 28 of every $100 in revenue as profit

P/E RatioValuation
15.2x8/10

Attractively priced relative to earnings

Free Cash FlowQuality
$1.82B8/10

Generating 1.8B in free cash flow

Areas to Watch

ETON4 concerns · Avg: 2.3/10
Market CapQuality
$628.09M3/10

Smaller company, higher risk/reward

Price/BookValuation
24.9x2/10

Trading at 24.9x book value

Return on EquityProfitability
-18.2%2/10

ROE of -18.2% — below average capital efficiency

EPS GrowthGrowth
-12.6%2/10

Earnings declined 12.6%

MRK3 concerns · Avg: 2.3/10
Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

PEG RatioValuation
3.362/10

Expensive relative to growth rate

EPS GrowthGrowth
-19.3%2/10

Earnings declined 19.3%

Comparative Analysis Report

WallStSmart Research

Bull Case : ETON

The strongest argument for ETON centers on Revenue Growth, Operating Margin. Revenue growth of 82.7% demonstrates continued momentum.

Bull Case : MRK

The strongest argument for MRK centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 28.1% and operating margin at 32.8%.

Bear Case : ETON

The primary concerns for ETON are Market Cap, Price/Book, Return on Equity.

Bear Case : MRK

The primary concerns for MRK are Piotroski F-Score, PEG Ratio, EPS Growth.

Key Dynamics to Monitor

ETON profiles as a hypergrowth stock while MRK is a value play — different risk/reward profiles.

ETON carries more volatility with a beta of 0.97 — expect wider price swings.

ETON is growing revenue faster at 82.7% — sustainability is the question.

MRK generates stronger free cash flow (1.8B), providing more financial flexibility.

Bottom Line

MRK scores higher overall (59/100 vs 35/100), backed by strong 28.1% margins. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Eton Pharmaceuticals Inc

HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA

Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and marketing pharmaceuticals for rare diseases. The company is headquartered in Deer Park, Illinois.

Merck & Company Inc

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.

Visit Website →

Want to dig deeper into these stocks?